With the recent development of agonists targeting GLP‐1 and GIP receptors for the treatment of type 2 diabetes and obesity, and the ongoing development of new incretin‐based drugs with improved efficacy, there is great interest in understanding the physiology and pharmacology of these hormones. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.